André Schiefner

Title: André Schiefner: Innovative Mind behind Anticalins

Introduction

André Schiefner, an accomplished inventor based in Nuremberg, Germany, has made significant contributions to the field of biotechnology. With a keen focus on innovative solutions, he holds a notable patent that addresses important medical applications.

Latest Patents

André Schiefner holds a patent for "High affinity anticalins directed against human CD98hc." This invention pertains to a specific binding protein aimed at the cluster of differentiation 98 heavy chain (CD98hc). The binding protein is derived from lipocalin 2 and exhibits a binding affinity with a Kd of 200 nM or lower, showcasing its potential for therapeutic applications in targeting CD98hc.

Career Highlights

Schiefner is affiliated with the Technische Universität München, where he collaborates with leading researchers to drive forward innovative research in biotechnology. His focus on binding proteins has marked him as a pivotal figure in the development of novel biopharmaceuticals.

Collaborations

He works closely with Friedrich-Christian Deuschle, leveraging their combined expertise to develop pioneering research that seeks to address critical challenges in health and medicine. Their collaboration underscores the importance of teamwork in advancing scientific innovation.

Conclusion

André Schiefner's contributions to the field of biotechnology, particularly through his patent on high affinity anticalins, represent a significant step forward in therapeutic innovations. His ongoing work at the Technische Universität München emphasizes the role of collaborative research in driving impactful changes in medical science.